§ Neovacs receives an upfront fee and is eligible for additional milestone payments and double digit sales royalties

§ Biosense receives option for development and commercial rights to IFNαKinoid for lupus and dermatomyositis in China and other selected territories

Paris, February 21, 2017 - Neovacs (Alternext Paris: ALNEV),a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has signed with BioSense Global LLCa commercial license option agreement for its IFNαKinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.

Neovacs SA published this content on 21 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 February 2017 09:39:03 UTC.

Original documenthttp://neovacs.fr/neovacs-and-biosense-sign-option-agreement-worth-up-to-e65-million-plus-royalties-for-chinese-development-and-commercial-rights-to-ifnα-kinoid-for-lupus-and-dermatomyositis/

Public permalinkhttp://www.publicnow.com/view/86E174C38C3192100F7027C8BA7362FA4147CBA6